Biosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™

The biosimilars market is projected to grow to $70.79B by 2036 from $37.39B in 2026 (6.6% CAGR), supported by faster manufacturing/analytical tech and evolving quality/regulatory frameworks. Growth is expected to be led by North America (11.5% CAGR), with oncology as the fastest-growing indication and monoclonal antibodies showing the highest CAGR (2026–2036). The sector’s funding and deal activity highlight capacity buildouts—e.g., Sandoz investing $1.1B+ in Slovenia through 2029—and consolidation, including Sun Pharma’s $11.75B acquisition of Organon, reinforcing competitive intensity post patent expiry.

Analysis

The important takeaway is not the market-size math; it is that biosimilars are becoming a scale-and-execution business, not a science-only business. That shifts economics toward players with manufacturing depth, regulatory muscle, and enough portfolio breadth to absorb tender-driven price erosion. In that setup, the winners are likely the platforms that can cross-subsidize launches and keep supply reliable, while smaller developers risk monetizing their pipelines at much lower margins than the top-line CAGR implies.

The second-order read is mixed for the public names. SDZNY and ALVO have the cleanest operating leverage to U.S. adoption, but the real spread opportunity is against weaker, more generic-heavy competitors whose biosimilar programs do not move the group P&L enough to offset falling ASPs elsewhere. AMRX has strategic optionality from its recent asset build, but integration and milestone economics mean the equity story is still more about pipeline credibility than near-term earnings acceleration.

For originators and diversified pharmas, the hit is slower but persistent: the danger is multiple compression as the market starts capitalizing lower long-run exclusivity rents, not an immediate revenue shock. The contrarian miss is that growth in this category can coexist with weak profit pools if competition, rebates, and hospital tendering intensify faster than volume expands. The key falsifier is evidence that North American adoption improves without a meaningful discount war or that interchangeability/reimbursement bottlenecks keep biosimilar penetration below current optimism.

Key Decisions for Investors

• Pair trade over 3-6 months: long SDZNY / short TEVA. Thesis is that biosimilars reward manufacturing scale and portfolio focus more than generic-heavy complexity; risk/reward improves if U.S. adoption and launch cadence accelerate.
• Tactical long ALVO only on pullbacks and only as a small position for 6-12 months. The upside is operating leverage to mAb biosimilar growth; the main risk is execution, cash burn, and delayed commercialization.
• Use AMRX as an event-driven watchlist name rather than a core long. Add only if post-close integration commentary shows faster-than-expected biosimilar revenue contribution; otherwise the milestone structure can dilute equity upside.
• Do not chase AMGN, PFE, or LLY on this theme. Treat them as potential financing/hedge shorts against a biosimilar basket only if future data show faster U.S. penetration and worsening originator pricing.